Introduction
============

Liquid chromatography-mass spectrometry has been widely applied in pharmaceutical and clinical metabolomics to comprehensively reveal metabolic alteration in given biological system ([@B43]; [@B13]; [@B56]; [@B69]), identify biomarkers and therapeutic targets for a variety of complex diseases ([@B77]; [@B68]; [@B21]; [@B31], [@B37]) and illuminate mechanism of action of drugs or drug candidates ([@B7]; [@B34]; [@B35]; [@B67]; [@B71]). Because of the extended period of clinical data collection and huge size of analyzed samples, the long-term and large-scale metabolomic profiling is frequently encountered in current medical study to identify physiological perturbation in various living systems ([@B75]; [@B76]), analyze time-dependency of metabolic alteration ([@B19]; [@B16]) and evaluate therapy and patient stratification in personalized medicine ([@B29]; [@B59]). Data from large-scale metabolomics are generally collected over long period varying from months to years and must be divided into batches, which requires a comprehensive consideration of all data of various batches or studies ([@B4]; [@B36]). So far, *ReIn* of multiple experiments in large-scale metabolomics has been applied to enhance the reliability and robustness in cancer-related metabolites profiling ([@B14]; [@B66]) and marker discovery for prediabetes or diabetes patients ([@B15]; [@B60]).

However, *ReIn* precludes the reanalysis of original data due to the lack of quantitative metabolomics data and inevitably results in inadequate statistical power ([@B14]). Due to the necessity of quantitative data, a database named *MetaboLights* providing such information has been established ([@B23]), which makes the reanalysis or integrated analysis of the quantitative data possible and convenient ([@B18]). Based on our comprehensive investigation on all metabolomics studies in *MetaboLights* ([Figure 1](#F1){ref-type="fig"}), the sample sizes of the majority (\>65%) and almost half (\>45%) of these studies are less than 100 and 50, respectively. As reported, a total cohort of over 100 samples is essential for the identification of a maximum of statistically significant variations in any metabolic exploration ([@B3]). Since the bias of current metabolic explorations is reported to come frequently from the inadequacy of studied samples ([@B72]; [@B52]), there is an urgent need to maximally enlarge the sample size and in turn enhance the statistical power of a given metabolomics study ([@B5]).

![Distribution of the sample sizes of all (gray) and human (green) metabolomics studies publicly available in the *Metabolights* database.](fphar-10-00127-g001){#F1}

Till now, *DiMe* strategy has been adopted in OMIC studies which effectively enlarges the size of studied samples ([@B27]; [@B33]; [@B53]). In particular, new breast cancer biomarkers are identified by combining RNA-seq gene expression data ([@B53]); novel alternative splicing is found by collectively analyzing multiple RNA-seq datasets ([@B33]); the removal of batch effects from transcriptomics data is investigated by microarray data integration ([@B27]). Due to the enlargement of studied samples, *DiMe* demonstrates potential enhancements in the accuracy, consistency and robustness of OMIC data analysis ([@B26]; [@B14]), and is proposed to significantly increase statistical power, reduce experimental bias, enhance reproducibility and improve overall biological understanding ([@B75]). However, compared with *ReIn*, the *DiMe* of multiple experiments has not yet been widely used in current metabolomics studies, which may be attributed to two major factors ([@B75]; [@B30]). The first is the difficulty in removing the unwanted variations among experiments and inexistence of prior knowledges on the performance of the available merging methods ([@B75]). In other word, it is still elusive whether the *DiMe* can effectively enhance the performance of metabolic profiling ([@B51]). The second is the existence of multiple criteria to assess the performance of *DiMe* and the great difficulty of selecting the optimal one ([@B30]; [@B57]). As reported, a multiple criteria evaluation is more effective than the single one in assessing the reliability of integration ([@B28]), and a collective consideration of multiple criteria is therefore recommended to thoroughly evaluate the applied strategy from different perspectives ([@B30]; [@B57]). All in all, because of the distinct underlying theory of these criteria, it is very essential to systematically assess the performance of *DiMe* strategy by collectively considering all criteria.

In the study, comprehensive evaluation of different analytical strategies was conducted by assessing their *classification capacity, robustness* and *false discovery rate*. First, based on a systematic review of *MetaboLights* a number of benchmark studies were identified to accomplish this assessment. Then, the integration/merging-based strategies (*ReIn* and *DiMe*) together with the strategies based on single experiment were collectively evaluated by multiple criteria. In conclusion, these findings provided a valuable guidance to the selection of suitable analytical strategy in a given metabolomics study.

Materials and Methods {#s1}
=====================

Collection of Metabolomics Datasets to Assess the Performance of *DiMe* Strategy
--------------------------------------------------------------------------------

A systematic search in the *MetaboLights* database ([@B18]) was collectively conducted to discover benchmark datasets for the performance assessment of *DiMe*. First, the *MetaboLights* was searched by the keyword "mass spectrometry," which resulted in 339 projects (September 16, 2018). Second, several criteria were used to ensure the availability and processability of raw metabolomics data, which included (a) complete set of raw data files, (b) well-defined parameters (mz value, range of retention time), (c) enough samples (\>10) in each experiment, (d) same classes of both cases and controls in different experiments, and (e) clear description on the sample groups. The application of the above criteria to those 339 projects resulted in eight benchmark metabolomics datasets of varied sample sizes. In particular, these eight datasets included (1) a UPLC-QTOF MS dataset based on the serums of 59 patients of HCC and 129 CIR patients collected at Georgetown University Hospital (GUH) and run in positive mode from an experiment conducted in May 2010 ([@B65]), (2) a metabolomics benchmark dataset of the MS positive mode based on the serums of 13 HCC and 50 CIR patients collected at GUH in July 2010 ([@B65]), (3) a UPLC-QTOF MS dataset based on the serums of 59 HCC and 129 CIR patients collected at GUH and run in negative mode from an experiment conducted in May 2010 ([@B65]), (4) the benchmark dataset of MS negative mode based on the serums of 13 HCC and 50 CIR patients collected at GUH in July 2010 ([@B65]), (5) the UPLC-QTOF MS dataset based on the serums of 20 HCC and 25 CIR patients collected from Egypt and run in positive mode ([@B65]), (6) the metabolomics benchmark dataset of the MS positive mode based on the serums of 20 HCC and 24 CIR patients collected in Egypt ([@B65]), (7) UPLC-QTOF MS dataset based on the serums of 20 HCC and 25 CIR patients collected in Egypt and run in negative mode ([@B65]), and (8) the benchmark dataset of MS negative mode based on the serums of 20 HCC and 24 CIR patients collected from Egypt ([@B65]).

Direct Data Merge (*DiMe*) Strategy Used in This Study Based on the m/z Values
------------------------------------------------------------------------------

The workflow of the *DiMe* strategy applied in this work was systematically illustrated in [Figure 2a](#F2){ref-type="fig"}. In this study, four pairs of metabolomics benchmark datasets were adopted to assess the performance of *DiMe* strategy, which included the pair of experimental dataset (1) and dataset (2) from MTBLS17 ESI+ ([@B18]), the pair of experimental dataset (3) and dataset (4) from MTBLS17 ESI- ([@B18]), the pair of experimental dataset (5) and dataset (6) from MTBLS19 ESI+ ([@B18]), and the pair of experimental dataset (7), and dataset (8) from MTBLS19 ESI- ([@B18]). In each experimental dataset, the peak detection, retention time (RT) correction and peak alignment were first applied to the UHPLC/Q-TOF-MS raw data (in CDF format) using the *xcmsSet, group* and *rector* functions in XCMS package ([@B49]) by setting both *fwhm* and *bw* equal to ten ([@B32]). Then, two datasets in each pair were merged based on their m/z values with tolerance of 0.05 ppm ([@B73]). In particular, the common peaks within above tolerance between two datasets was selected, based on which these datasets were merged into a large one.

![Schematic representations of the workflows of the analytical strategies applied in this study. **(a)** the pipeline of direct merge; **(b)** the pipeline of results integration.](fphar-10-00127-g002){#F2}

Prior to the biomarker identification, the datasets were frequently pretreated in current metabolomics study ([@B10]; [@B78]; [@B79]). Herein, the pretreatment of merged dataset was then conducted, which included the missing value imputation using k-Nearest Neighbor (KNN) method and data normalization using MSTUS. The KNN method imputed values based on K features similar to the features with missing values ([@B47]). Among the available imputation methods, the KNN algorithm was reported as the most robust one for analyzing MS-based metabolomic data ([@B11]). By assuming that the number of increased and decreased metabolic signals is relatively equivalent, the MSTUS adopted the total signal of metabolites that was shared by all samples ([@B61]). MSTUS was referred as one of the best choices for overcoming sample variability in urinary metabolomics and was used to identify diagnostic and prognostic biomarkers ([@B8]; [@B41]). Therefore, the KNN algorithm and the MSTUS method were adopted in this study to impute the missing signal of metabolite and transform/normalize the data matrix. After the above preparation, the training, testing and independent test datasets were further constructed based on the random sampling of the merged dataset. These three datasets were prepared for assessing the *identification precision* and *classification capacity* of *DiMe* strategy (described in the last section of "Materials and Methods"). Furthermore, another 10 datasets were generated by the random sampling of half of the merged dataset for 10 times, which were further used for evaluating the *robustness* of *DiMe* strategy (described in the last section of "Materials and Methods").

After all those steps prepared above, the PLSDA was used to identify the differential metabolic peaks between distinct sample groups within each merged dataset. Particularly, the differential peaks were identified by VIP \>1 and *p*-value \< 0.05 ([@B12]), which were subsequently annotated based on human metabolome database (HMDB) ([@B62]) by setting m/z tolerance equal to 20 ppm ([@B45]). Those resulting metabolites annotated were the metabolic biomarkers finally identified. All in all, the workflow of *DiMe* strategy applied in this study was systematically illustrated in [Figure 2a](#F2){ref-type="fig"}.

Results Integration (*ReIn*) Strategy Used in This Study Based on the Identified Biomarkers
-------------------------------------------------------------------------------------------

The workflow of the *ReIn* strategy applied in this work was systematically illustrated in [Figure 2b](#F2){ref-type="fig"}. The same four pairs of metabolomics benchmark datasets as used in *DiMe* strategy were used in this analysis. For the experimental dataset in each pair, peak detection, RT correction and peak alignment were first conducted using the *xcmsSet, group* and *rector* functions in XCMS package ([@B49]) by setting *fwhm* and *bw* to ten ([@B32]). Second, the pretreatment of each experimental dataset was conducted using KNN for missing value imputation and MSTUS for data normalization. Third, the training, testing and independent test datasets were constructed by random sampling each pretreated experimental dataset. These three datasets were prepared for assessing the *identification precision* and *classification capacity* of the *ReIn* strategy (described in the last section of "Materials and Methods"). Meanwhile, another 10 datasets were generated by the random sampling of half of the pretreated experimental dataset for 10 times, which were applied for the evaluation of *robustness* of the *ReIn* strategy (described in the last section of "Materials and Methods"). Fourth, PLSDA was used to identify the differential metabolic peaks between distinct sample groups within each dataset (VIP\>1 and *p*-value \< 0.05). The resulting metabolites annotated based on HMDB by setting the m/z tolerance equal to 20 ppm were the metabolic biomarkers finally identified. Finally, the metabolites annotated from two experimental datasets were collectively considered for assessing *identification precision* of the *ReIn* strategy, the classification models constructed based on experimental datasets were integrated for evaluating *ReIn*'s *classification capacity*, and the *robustness* of the *ReIn* strategy was also collectively determined by the average overlap values between two experiments. All in all, the workflow of *ReIn* strategy applied in this study was systematically illustrated in [Figure 2b](#F2){ref-type="fig"}.

Multiple Criteria Used for the Performance Assessment of the Strategies Applied
-------------------------------------------------------------------------------

Three well-established criteria for the performance assessment of the strategies applied were adopted in this study, which included the *identification precision, classification capacity* and *robustness*. As reported, these three criteria were independent from each other ([@B30]), which was required to be collectively considered during the performance assessments ([@B55]). In other words, these three criteria were mutually complemental from different perspectives, and all were important for assessing the performance of the analytical strategy applied in metabolomic studies ([@B55]). Therefore, all these criteria were adopted in this study for performance assessment.

### Identification Precision

Recent studies emphasized the importance of the experimentally validated true markers in evaluating the identification precision of analytical strategies ([@B32]; [@B6]; [@B30]). These well-established true metabolic markers were then used as a golden standard to assess the identification precision based on the EF ([@B74]; [@B38]). The EF was used to measure the enhanced chances of true marker identification by a given analytical strategy over the random selection of true markers from all metabolites ([@B74]; [@B38]). In this study, a comprehensive literature review on the experimentally validated true markers differentiating HCC patients from those with CIR was first conducted. Then, the EF of each analytical strategy was calculated based on Eq. 1:
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EF denoted the level of enhancement in true marker identification rate ([@B74]). EF = 1 meant no better than random selection. The larger EF, the greater the likelihood to find true marker.

### Classification Capacity

Based on three datasets after "dataset construction" ([Figure 2](#F2){ref-type="fig"}), the SVM was first applied to construct the classification model based on both training and testing datasets together with the biomarkers identified by Student's *t*-test (*p*-value \< 0.05). Then, independent test set was used to assess the classification capacity of constructed model, which was evaluated by the ROC analysis together with the measurement of AUC ([@B25]). The AUC values were widely considered to be one of the most objective and valid metrics for the performance evaluation of biomarker discovery ([@B64]). Moreover, the classification capacity was frequently assessed by four popular metrics including the SEN, SPE, accuracy (ACC), MCC. Particularly, SEN was defined by the percentage of true positive samples correctly identified as "positive" (shown in Eq. 2); SPE denoted the proportion of true negative samples that were correctly predicted as "negative" (shown in Eq. 3); ACC indicated the number of true samples (positive plus negative) divided by the number of all studied samples (shown in Eq. 4); MCC reflected the stability of classification capacity, which described the correlation between a predictive value and an actual value (shown in Eq. 5).
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where TP, TN, FP, and FN denoted the number of true positive samples, true negative samples, false positive samples and false negative samples, respectively.

### Robustness

First, ten sub-datasets were generated by the random sampling of half of the pretreated experimental/merged dataset for ten times. Second, the biomarkers were identified using Student's *t*-test (*p*-value \< 0.05) for each dataset, and ten lists of biomarkers were discovered. Third, for any 2 marker lists, the fraction of shared marker appearing on both lists were used to measure the similarity of these two lists. Particularly, *overlap* value was calculated (shown in Eq. 6) based on marker lists a and b. The closer the *overlap* value equal to 1, the more robust the markers discovered in that study ([@B58]). For each experimental/merged dataset, 45 (C~1~0^2^ ) *overlap* values denoting all possible combinations between any two sub-datasets were thus calculated and analyzed here.
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where a and b indicated two maker lists, and Na and Nb denoted the number of markers in each list.

Results and Discussion
======================

Comparative Analysis on the Classification Capacities of the Constructed Models
-------------------------------------------------------------------------------

Classification model was frequently constructed in current metabolomics research to predict samples of different disease states ([@B9]; [@B42]) or assess the reliability of identified metabolic markers ([@B50]). The capacities of the constructed classification model were evaluated by various metrics including *ACC, SEN, SPE, MCC, ROC*, and the area under ROC curve (*AUC* value) ([@B17]; [@B20]; [@B70]). As illustrated in [Figure 2](#F2){ref-type="fig"}, four different analytical strategies, including two strategies based on datasets collected from single experiment (SiE1 and SiE2) and two additional strategies of *ReIn* and *DiMe*, were first evaluated by calculating their *ACC, SEN, SPE*, and *MCC*. As shown in [Table 1](#T1){ref-type="table"}, there was great variation in each assessment metric among four strategies and among four benchmark datasets. Particularly, the *ACCs, SENs, SPEs*, and *MCCs* of MTBLS17-POS were in the ranges of 0.59∼0.80, 0.33∼0.58, 0.59∼0.92, and 0.12∼0.50 among strategies, respectively, and that of *DiMe* was estimated to be within 0.72∼0.80, 0.50∼0.82, 0.77∼1.00, and 0.44∼0.60 among datasets, respectively. The metrics *ACC* and *MCC* were frequently adopted in current metabolomics to evaluate correctness ([@B1]) and stability ([@B63]) of constructed prediction models. As demonstrated in [Table 1](#T1){ref-type="table"}, the *ACCs* of *DiMe* were in the range of 0.72∼0.80, which were substantially and consistently higher than that of the other 3 strategies (0.56∼0.74). Similar to *ACCs*, the *MCCs* of *DiMe* (0.44∼0.60) were discovered to be robustly higher than that of the other strategies (0.06∼0.32), and the majority (75%) of *DiMe*'s *MCCs* were larger than 0.50.

###### 

Classification capacities of different analytical strategies assessed by accuracy (ACC), sensitivity (SEN), specificity (SPE), Matthews correlation coefficient (MCC) and area under the curve (AUC) based on four pairs of benchmark datasets collected from the *Metabolights* database.

  Experiment ID     ACC    SEN    SPE    MCC    AUC    
  ----------------- ------ ------ ------ ------ ------ ------
  **MTBLS17-NEG**   SiE1   0.74   0.67   0.75   0.32   0.79
  SiE2              0.69   0.33   0.80   0.13   0.60   
  *ReIn*            0.73   0.60   0.76   0.29   0.70   
  *DiMe*            0.78   0.82   0.77   0.53   0.85   
                                                       
  **MTBLS17-POS**   SiE1   0.59   0.58   0.59   0.13   0.57
  SiE2              0.69   0.33   0.80   0.13   0.76   
  *ReIn*            0.60   0.53   0.62   0.12   0.66   
  *DiMe*            0.80   0.53   0.92   0.50   0.83   
                                                       
  **MTBLS19-NEG**   SiE1   0.67   0.50   0.80   0.32   0.80
  SiE2              0.56   0.50   0.60   0.10   0.80   
  *ReIn*            0.61   0.50   0.70   0.20   0.80   
  *DiMe*            0.78   0.50   1.00   0.60   0.93   
                                                       
  **MTBLS19-POS**   SiE1   0.56   0.25   0.80   0.06   0.70
  SiE2              0.67   0.50   0.80   0.32   0.75   
  *ReIn*            0.61   0.38   0.80   0.19   0.73   
  *DiMe*            0.72   0.50   0.90   0.44   0.88   
                                                       

Apart from *ACC* and *MCC*, the *ROC* and *AUC* were two other popular metrics widely used to assess classification ability, which were acknowledged to achieve a comprehensive performance evaluation. As illustrated in [Figure 3](#F3){ref-type="fig"}, the *ROC* curves and the *AUC* values of 4 benchmark datasets (MTBLS17-NEG, MTBLS17-POS, MTBLS19-NEG, and MTBLS19-POS) were compared. Two benchmark sets (MTBLS17-NEG and MTBLS17-POS) contained 503 samples (including 358 and 145 patients with liver cirrhosis and HCC, respectively), and the other datasets MTBLS19-NEG and MTBLS19-POS consisted of 180 samples (100 patients with liver cirrhosis and 80 patients with HCC). The gray diagonals represented an invalid model with the corresponding AUC value equaled to 0.5. As shown in [Table 1](#T1){ref-type="table"}, the *AUC* values of *DiMe* among different datasets (0.82∼0.93) were substantially and consistently higher than that of the other 3 strategies (0.57∼0.80), which were similar to the results assessed by *ROC* curves. In conclusion, this finding indicated that classification correctness (assessed by *ACC, ROC*, and *AUC*) and prediction stability (evaluated by *MCC*) of the direct merge strategy (*DiMe*) were found consistently better across multiple benchmark datasets compared with the SiE1 and SiE2 strategies and the one of results integration (*ReIn*).

![Classification capacities of different analytical strategies assessed by receiver operating characteristic (ROC) and area under the curve (AUC) based on four pairs of benchmark datasets collected from the *Metabolights* database.](fphar-10-00127-g003){#F3}

Robustness Assessment of the Markers Identified by Different Analytical Strategies
----------------------------------------------------------------------------------

Apart from prediction capacity evaluated simultaneously by classification correctness and prediction stability, the robustness of identified metabolic markers was widely accepted to be another important metric with underlying theory distinct from that of prediction capacity ([@B30]; [@B57]). So far, *overlap* value had been recognized as the quantitative measure of the robustness of the identified markers ([@B58]). The higher *overlap* values represented the more robust metabolic markers identified from a particular dataset by a given strategy. In this study, a sub-dataset was first generated by randomly selecting 50% of both cases and controls in each benchmark dataset, and ten iterations of this selection procedure resulted in ten sub-datasets. For each sub-dataset, a list of differentially expressed metabolic markers were then identified by Student's *t*-test (*p*-value \< 0.05), and the value of *overlap* between any two sub-datasets was calculated using their corresponding lists of markers identified. In total, there were 45 ($C_{10}^{2}$) *overlap* values denoting all possible combinations between any two sub-datasets. Finally, the *overlap* values of four different analytical strategies were compared. As shown in [Table 2](#T2){ref-type="table"}, the total numbers of markers identified by ten sub-datasets together with the median values of *overlap* were provided. It was obvious that the total numbers of identified markers among ten sub-datasets varied significantly (from 11 to 334). Moreover, although there was great difference among the median *overlap* values (from 0.15 to 0.40), the median *overlap* of *DiMe* was found consistently larger than that of the other three strategies.

###### 

Robustness of different analytical strategies assessed by the number of markers selected by each sampling set and overlap values based on four pairs of benchmark datasets collected from the *Metabolights* database.

  Experiment ID   No. of Cases/Controls   No. of MS Peaks Detected   No. of markers selected by the *n*th sampling set   Overlap Median across 10 Samplings                                                               
  --------------- ----------------------- -------------------------- --------------------------------------------------- ------------------------------------ ----- ----- ----- ------ ----- ----- ----- ----- ---------- ----------
  **MTBLS17-N**   SiE1                    59/129                     941                                                 216                                  219   74    87    135    276   63    70    42    96         **0.32**
  SiE2            13/50                   1,209                      37                                                  107                                  50    135   47    170    60    64    129   64    **0.15**   
  *ReIn*          72/179                  941/1,209                  127                                                 163                                  62    111   91    223    62    67    86    80    **0.23**   
  *DiMe*          72/179                  734                        145                                                 81                                   53    115   57    95     57    66    54    125   **0.40**   
                                                                                                                                                                                                                          
  **MTBLS17-P**   SiE1                    60/129                     1,586                                               161                                  141   43    84    113    43    114   66    114   195        **0.23**
  SiE2            13/50                   3,230                      128                                                 161                                  597   179   173   140    291   167   278   233   **0.21**   
  *ReIn*          73/179                  1,586/3,230                145                                                 151                                  320   132   143   92     203   117   196   214   **0.19**   
  *DiMe*          73/179                  1,144                      173                                                 68                                   334   107   82    112    90    106   109   106   **0.36**   
                                                                                                                                                                                                                          
  **MTBLS19-N**   SiE1                    20/25                      883                                                 34                                   51    53    56    39     23    179   73    118   123        **0.27**
  SiE2            20/24                   825                        27                                                  114                                  139   216   42    60     22    112   12    32    **0.21**   
  *ReIn*          40/50                   883/825                    31                                                  83                                   96    136   41    41.5   101   93    65    78    **0.26**   
  *DiMe*          40/50                   665                        66                                                  11                                   57    187   109   47     27    60    76    37    **0.31**   
                                                                                                                                                                                                                          
  **MTBLS19-P**   SiE1                    20/25                      1,526                                               57                                   104   63    91    74     164   86    76    37    52         **0.19**
  SiE2            20/24                   1,542                      229                                                 77                                   34    187   170   150    80    248   175   57    **0.22**   
  *ReIn*          40/50                   1,526/1,542                143                                                 91                                   49    139   122   157    83    162   106   55    **0.23**   
  *DiMe*          40/50                   872                        132                                                 29                                   110   80    102   148    206   110   163   146   **0.39**   
                                                                                                                                                                                                                          

Compared with the median value of *overlap*, the statistical difference of 45 *overlap* values between different analytical strategies was more meaningful to reveal the level of robustness for each strategy. Thus, comprehensive statistical comparison of robustness among different strategies was conducted and illustrated in [Figure 4](#F4){ref-type="fig"}. The *overlap* values of SiE1, SiE2, *ReIn*, and *DiMe* were colored in light green, dark green, blue, and orange, respectively. Apart from the enhanced median values of *overlap* by *DiMe*, all overlap values of *DiMe* were found statistically higher (*p*-value \< 0.05) compared with that of the other strategies. In particular, as illustrated in [Figure 4](#F4){ref-type="fig"}, the statistical differences between *DiMe* and other strategies (*p*-value) were always lower than 0.05 within the range from 4.25E-16 to 1.81E-02. Moreover, the majority of the *overlap* values of *DiMe* were larger than 0.3, while that of the other strategies were lower than 0.3. These findings indicated that the *DiMe* strategy performed better than others in the robustness of the identified markers. Additionally, [Table 3](#T3){ref-type="table"} demonstrated the information of markers simultaneously discovered by N (*N* ≥ 6, ≥ 7, ≥ 8, ≥ 9, = 10) sub-datasets, which included the number and percentage of markers co-identified by these N datasets. It was very clearly to see that the robustness of metabolic markers identified by *DiMe* was much better than other three strategies in terms of both the number and the percentage of co-identified markers. Particularly, the percentages of markers identified by over five sub-datasets using *DiMe* were within 3.25%∼5.07%, while that using SiE1 and SiE2 were 0.87%∼2.74% and 0.93%∼2.06%, respectively. Moreover, the percentages of markers identified by all sub-datasets using *DiMe* were within 0.00%∼0.41%, while that using SiE1 and SiE2 were 0.00%∼0.25% and 0.00%∼0.21%, respectively.

![Robustness of different analytical strategies assessed by the overlap values based on four pairs of benchmark datasets collected from the *Metabolights* database.](fphar-10-00127-g004){#F4}

###### 

Robustness of different analytical strategies assessed by the percent and number of markers discovered simultaneously by multiple sampling datasets based on four pairs of benchmark datasets collected from the *Metabolights* database.

                                                                                 MTBLS17-NEG   MTBLS17-POS   MTBLS19-NEG   MTBLS19-POS                                                                                             
  ------------------------------------------------------------------------------ ------------- ------------- ------------- ------------- ------------ ------------ ------------ ------------ ------------ ----------- ------------ ------------
  **No. of markers identified**                                                  **1,278**     **863**       **848**       **1,074**     **2,347**    **1,287**    **749**      **776**      **677**      **804**     **1,407**    **1,226**
                                                                                                                                                                                                                                   
  **Percent (No.) of makers discovered simultaneously by N datasets (*N* = )**                                                                                                                                                     
  10                                                                             0.00% (0)     0.00% (0)     0.12% (1)     0.09% (1)     0.00% (0)    0.31% (4)    0.00% (0)    0.00% (0)    0.00% (0)    0.25% (2)   0.21% (3)    0.41% (5)
  ≥9                                                                             0.31% (4)     0.00% (0)     1.30% (11)    0.19% (2)     0.09% (2)    1.01% (13)   0.80% (6)    0.00% (0)    1.18% (8)    0.37% (3)   0.36% (5)    1.14% (14)
  ≥8                                                                             0.70% (9)     0.35% (3)     2.48% (21)    0.56% (6)     0.34% (8)    1.55% (20)   1.20% (9)    0.13% (1)    1.77% (12)   0.37% (3)   0.50% (7)    1.55% (19)
  ≥7                                                                             1.17% (15)    0.35% (3)     4.01% (34)    0.93% (10)    0.64% (15)   2.87% (37)   1.34% (10)   0.52% (4)    2.07% (14)   0.62% (5)   1.07% (15)   2.45% (30)
  ≥6                                                                             2.74% (35)    0.93% (8)     5.07% (43)    2.05% (22)    1.15% (27)   3.81% (49)   2.00% (15)   1.29% (10)   3.25% (22)   0.87% (7)   2.06% (29)   4.24% (52)
                                                                                                                                                                                                                                   

Evaluation on the False Discovery Rates by Experimentally Validated True Markers
--------------------------------------------------------------------------------

Recent studies emphasized the importance of spike-in metabolites and experimentally validated true markers in evaluating the false discovery rates of analytical strategy ([@B32]; [@B6]; [@B30]). These well-established true metabolic markers were frequently used as the golden standard to assess the false discovery rates based on their identification EF ([@B74]; [@B38]). Hence, a comprehensive literature review on the experimentally validated true markers differentiating HCC patients from those with CIR was first conducted in this study. As a result, thirteen discriminative markers between HCC and CIR patients were identified ([Table 4](#T4){ref-type="table"}). As shown, some metabolic markers (like *glycochenodeoxycholic acid*) were identified from serum samples combining TOF MS/MS with UPLC-SRM-MS/MS based on the internal standard isotope dilution ([@B54]; [@B65]; [@B24]), and some other markers (like *16:0 lysophosphatidic acid* and *phenylalanine*) were detected by the targeted analysis based on UPLC-ESI-TQMS ([@B44]) and LC-MRM-MS/MS ([@B2]). *Carnitine* and *creatinine* were first discovered by analyzing urinary 1H MRS data ([@B48]), but *carnitine* was also identified as true marker in serum samples ([@B65]). Since the four benchmark datasets analyzed in this study were serum-based data, these experimentally validated true metabolic markers (twelve biomarkers in total, except *creatinine*, [Table 4](#T4){ref-type="table"}) were therefore used here to evaluate the false discovery rates of each analytical strategy.

###### 

A variety of metabolite biomarkers differentiating the patients of hepatocellular carcinoma (HCC) from those of cirrhosis (CIR) identified during the past ten years.

  No.   True metabolite markers differentiating HCC and CIR   HMDB ID   Bio-fluid used for marker identification   Experimental strategy applied for marker identification                                                                Reference
  ----- ----------------------------------------------------- --------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- -----------
  1     16:0 lysophosphatidic acid                            10382     Serum                                      Profiled and then identified by UPLC-ESI-TQMS based on the internal metabolite standard                                [@B44]
  2     18:0 lysophosphatidic acid                            10384     Serum                                      Combining the TOF MS/MS with UPLC-SRM-MS/MS using internal standard-based isotope dilution                             [@B24]
  3     Acetyl carnitine                                      00201     Serum/Urine                                Verified by acquiring MS/MS spectra and further confirmed based on the structure of commercial standard                [@B39]
  4     Carnitine                                             00562     Serum/Urine                                Discovered by serum-based isotope dilution using LC-MS/MS and analyzing the urine-based 1H MRS data                    [@B65]
  5     Creatinine                                            00062     Urine                                      Identified experimentally by statistically analyzing the urine-based 1H MRS data                                       [@B48]
  6     Glycochenodeoxycholic acid                            00637     Serum                                      Verified by acquiring MS/MS spectra and then quantified using internal standard-based isotope dilution by UPLC-MS/MS   [@B46]
  7     Glycocholic acid                                      00138     Serum                                      Verified by acquiring MS/MS spectra and then quantified using internal standard-based isotope dilution by UPLC-MS/MS   [@B46]
  8     Glycodeoxycholic acid                                 00631     Serum                                      Discovered by the serum-based isotope dilution integrating the internal standard with UPLC-SRM-MS/MS                   [@B65]
  9     Oleamide                                              02117     Serum                                      Experimentally validated and identified by UPLC-MS profiling of serum-based data                                       [@B22]
  10    Phenylalanine                                         00159     Serum                                      Detected from the serum samples based on the targeted analysis using LC-MRM-MS/MS                                      [@B2]
  11    Phenylalanyl-tryptophan                               29006     Serum                                      Identified by the targeted profiling using serum-based UPLC-MS and determined by isotope-labeled quantification        [@B40]
  12    Taurochenodeoxycholic acid                            00951     Serum                                      Discovered by the serum-based isotope dilution integrating the internal standard with UPLC-SRM-MS/MS                   [@B65]
  13    Taurocholic acid                                      00036     Serum                                      Verified by acquiring MS/MS spectra and then quantified using internal standard-based isotope dilution by UPLC-MS/MS   [@B46]
                                                                                                                                                                                                                                          

ESI: electrospray ionization; MRM: multiple reaction monitoring; MRS: magnetic resonance spectroscopy; SRM: selected reaction monitoring; TOF: time-of-flight; TQMS: triple quadrupole mass spectrometry; UPLC: ultraperformance liquid chromatography.

[Table 5](#T5){ref-type="table"} provided the number of the true makers covered by both detected and identified metabolites. For each experimental dataset (MTBLS17-NEG, MTBLS17-POS, MTBLS19-NEG, and MTBLS19-POS), there were variations in their number of true markers covered by the detected metabolites. In particular, the detected metabolites in MTBLS17-POS contained the highest number of true markers (11 for all strategies) and that in MTBLS17-NEG covered the most variated numbers of true markers among four strategies (from 5 to 9). Furthermore, the number of true markers identified by strategies SiE1 and SiE2 was found to be basically no less than that of *ReIn* and *DiMe*, which represented the relatively equal abilities in true marker identification among different strategies. However, as shown in [Table 5](#T5){ref-type="table"}, the EF of both SiE1 and SiE2 was consistently lower than that of *ReIn* and *DiMe*, which indicated that, compared with *ReIn* and *DiMe*, the total numbers of true markers discovered by SiE1 and SiE2 were more at the cost of discovering numerous false metabolites. Moreover, among those integration/merging-based strategies (*ReIn* and *DiMe*), the EF values of *ReIn* in three experimental datasets (MTBLS17-POS, MTBLS19-NEG, and MTBLS19-POS) were found to be obviously higher than those of *DiMe* strategy, which reflected the superior ability of *ReIn* strategy in controlling false discovery rate. However, in one extreme case (MTBLS17-NEG), the EF of *ReIn* was lower than that of *DiMe*. Careful investigation of [Table 5](#T5){ref-type="table"} revealed that only one true marker was identified by *ReIn*, which led to a huge decline in its EF values. Therefore, although *ReIn* demonstrated superior ability to control false discovery rate, its application could be limited by its relatively small number of true markers identified.

###### 

False discovery rate of different analytical strategies assessed by the number of true markers identified and the enrichment factor (EF) based on four pairs of benchmark datasets collected from the *Metabolights* database.

  Experiment ID     No. of cases / controls   No. of MS peaks detected   No. of metabolites annotated based on detected peaks   No. of true markers covered by detected metabolites   No. of differential peaks identified   No. of metabolites annotated based on identified peaks   No. of true markers covered by identified metabolites   Enrichment factor   
  ----------------- ------------------------- -------------------------- ------------------------------------------------------ ----------------------------------------------------- -------------------------------------- -------------------------------------------------------- ------------------------------------------------------- ------------------- ----------
  **MTBLS17-NEG**   SiE1                      59/129                     941                                                    42,269                                                9                                      172                                                      9709                                                    5                   **2.42**
  SiE2              13/50                     1,209                      43,614                                                 8                                                     174                                    3296                                                     2                                                       **3.31**            
  *ReIn*            72/179                    941/1,209                  32,592                                                 5                                                     \-                                     930                                                      1                                                       **7.01**            
  *DiMe*            72/179                    734                        34,840                                                 7                                                     141                                    2523                                                     4                                                       **7.89**            
                                                                                                                                                                                                                                                                                                                                                                  
  **MTBLS17-POS**   SiE1                      60/129                     1,586                                                  19,724                                                11                                     205                                                      6760                                                    7                   **1.86**
  SiE2              13/50                     3,230                      24,157                                                 11                                                    215                                    5815                                                     5                                                       **1.89**            
  *ReIn*            73/179                    1,586/3,230                19,724                                                 11                                                    \-                                     1862                                                     5                                                       **4.81**            
  *DiMe*            73/179                    1,144                      19,272                                                 11                                                    182                                    5503                                                     7                                                       **2.23**            
                                                                                                                                                                                                                                                                                                                                                                  
  **MTBLS19-NEG**   SiE1                      20/25                      883                                                    28,088                                                7                                      122                                                      5163                                                    3                   **2.33**
  SiE2              20/25                     825                        25,950                                                 7                                                     135                                    7049                                                     4                                                       **2.10**            
  *ReIn*            40/50                     883/825                    22,992                                                 7                                                     \-                                     1307                                                     2                                                       **5.03**            
  *DiMe*            40/50                     665                        23,040                                                 7                                                     107                                    1931                                                     2                                                       **3.41**            
                                                                                                                                                                                                                                                                                                                                                                  
  **MTBLS19-POS**   SiE1                      20/25                      1,526                                                  17,166                                                9                                      202                                                      4205                                                    5                   **2.26**
  SiE2              20/25                     1,542                      17,966                                                 8                                                     202                                    6028                                                     4                                                       **1.49**            
  *ReIn*            40/50                     1,526/1,542                15,215                                                 8                                                     \-                                     1789                                                     4                                                       **4.25**            
  *DiMe*            40/50                     872                        14,935                                                 8                                                     82                                     2469                                                     3                                                       **2.27**            
                                                                                                                                                                                                                                                                                                                                                                  

Conclusion
==========

Based on the systematic review of *MetaboLights*, a comprehensive evaluation of different analytical strategies was conducted by assessing the classification capacity, robustness and false discovery rate. As a result, the integration/merging-based strategies (*ReIn* & *DiMe*) performed better than strategies based on single experiment (SiE1 & SiE2). Moreover, *DiMe* strategy was found to outperform *ReIn* in *classification capacity* and *robustness*, while *ReIn* demonstrated superior capacity in controlling false discovery rate. In summary, these findings may facilitate current metabolomics study in *classification capacity, identification precision*, and *robustness*.
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